HCC Clinical Trial - Study of Serum Tumor Markers of HBV Associated HCC

Status Not yet recruiting

Clinical Trial Summary

In this study, the investigators will detect the expression of four potential HBV-related HCC biomarkers: PGIR,FAM3C,LAMB1 and SDC4 in tumor tissues and peripheral blood, to explore the specific molecular markers for the early diagnosis of HBV-related HCC.

Clinical Trial Description

Paired hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and adjacent liver tissues were selected, and the mRNA and protein expressions of the PGIR,FAM3C,LAMB1 and SDC4 biomarkers in tissues were detected by RT-PCR, western Blot and immunohistochemical analysis. At the same time, healthy subjects were selected as the control group, and mRNA and protein expression levels of the above molecules in blood were detected by RT-PCR and ELISA. At the same time, the correlation between the above biomarkers and the clinical data of patients, such as diagnosis, pathological grading, recurrence, metastasis and survival time was statistically analyzed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05825196
Study type	Observational
Source	Qianfoshan Hospital
Contact
Status	Not yet recruiting
Phase
Start date	May 1, 2023
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05458115` - Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
Not yet recruiting	`NCT05022628` - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis	Phase 4
Enrolling by invitation	`NCT02256514` - Open Label Trial of Immunotherapy for Advanced Liver Cancer	Phase 2
Not yet recruiting	`NCT06434480` - SBRT in HCC With Oligoprogression on Atezo-Bev	N/A
Completed	`NCT04542837` - The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma	Phase 2
Not yet recruiting	`NCT05025592` - cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
Completed	`NCT04172506` - A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors	Phase 1/Phase 2
Not yet recruiting	`NCT06024252` - Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
Not yet recruiting	`NCT05840133` - Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC
Terminated	`NCT02785874` - Statin With Palliative Therapy for HCC	N/A
Not yet recruiting	`NCT02715492` - Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.	Phase 3
Completed	`NCT02985034` - Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT	N/A
Not yet recruiting	`NCT06069947` - SALT for Liver Cirrhosis With HCC	N/A
Recruiting	`NCT05581004` - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	Phase 1
Suspended	`NCT02935478` - Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation	N/A
Recruiting	`NCT05592171` - Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC	N/A
Completed	`NCT03176485` - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors	N/A
Recruiting	`NCT05544253` - Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC	Phase 2/Phase 3
Recruiting	`NCT06184152` - CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
Completed	`NCT02675920` - A Study of HCC High Risk Group Using Two Surveillance Tools